Clinical Trials

Status
Published

Recently Activated

SHOW MORE

Active Filters

    Open
    Phase
    II
    Accrual
    0%
    SWOG Clinical Trial Number
    S2107

    Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

    Status Notes
    Activation Date: 06/06/2022
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    06-06-2022
    ClinicalTrials.gov Registry Number
    NCT05308446
    Open
    Accrual
    5%
    SWOG Clinical Trial Number
    S1800D

    A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

    Status Notes
    S1800D will open to accrual February 15, 2022, effective 12:00 pm PST. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    02-15-2022
    Open
    Phase
    II-III
    SWOG Clinical Trial Number
    A082002

    A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

    Status Notes
    This study is open to accrual on December 21, 2021.
    Research Committee(s)
    Lung Cancer
    Activated
    12-21-2021
    Open
    Phase
    II-III
    Accrual
    0%
    SWOG Clinical Trial Number
    S2012

    Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

    Status Notes
    Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
    Research Committee(s)
    Early Therapeutics & Rare Cancers
    Activated
    12-02-2021
    ClinicalTrials.gov Registry Number
    NCT05058651
    Open
    Phase
    III
    Accrual
    0%
    SWOG Clinical Trial Number
    S2011

    Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL

    Status Notes
    The study referenced above is open for participant accrual effective October 6th, 2021, at 12:00 p.m. Eastern Time.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    10-06-2021
    ClinicalTrials.gov Registry Number
    04871529
    Open
    Accrual
    0%
    SWOG Clinical Trial Number
    S1934

    NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer

    Status Notes
    S1934 will reactivate 02/15/2022.
    Research Committee(s)
    Lung Cancer
    Activated
    09-09-2021
    ClinicalTrials.gov Registry Number
    04989283